Jeanie Herbert | Head of Investor Relations |
Mark Foley | President & Chief Executive Officer |
Toby Schilke | Chief Financial Officer |
Dustin Sjuts | Chief Commercial Officer, Therapeutics & Aesthetics |
Ken Cacciatore | Cowen & Company |
Annabel Samimy | Stifel |
Terence Flynn | Goldman Sachs |
David Amsellem | Piper Sandler |
Kush Patel | Guggenheim |
Tim Lugo | William Blair |
Serge Belanger | Needham & Company |
Balaji Prasad | Barclays |
Chris Bialas | H.C. Wainwright |
Welcome to the Revance Therapeutics Third Quarter 2020 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following managements' prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, today's call is being recorded today, November 9, 2020. I would now like to turn the conference over to Jeanie Herbert, Head of Investor Relations for Revance.